Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC
Status:
COMPLETED
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This study is a real-world, single-arm, observational study primarily collecting data on patients with hepatocellular carcinoma who experienced disease progression after receiving lenvatinib in combination with PD-1 inhibitors as part of routine clinical practice, and evaluating the efficacy of adding lenalidomide to their treatment regimen.